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Clinical trialWe tested an inactivated egg-grown whole virus influenza A/H5N1 vaccine candidate developed by the
Institute of Vaccines and Medical Biologicals (IVAC), a state-run vaccine manufacturer in Vietnam, in a
Phase 1, placebo controlled, double blinded, randomized trial. The vaccine was adjuvanted with alu-
minum hydroxide. The trial enrolled 75 subjects who were randomized to receive two injections of
one of the following: low-dose of vaccine (7.5 mcg HA), high-dose of vaccine (15 mcg HA), or placebo.
The vaccine candidate was well tolerated with minimal local reactogenicity consisting of mild, short-
lived injection site pain and/or tenderness. No systemic reactogenicity was observed other than transient
low-grade fever in about 13% of the subjects and no unsolicited adverse events were attributable to pro-
duct administration. Immune responses were assessed at baseline and after the first and second dose by
hemagglutination inhibition (HAI) and microneutralization (MN) assays, with 72% of the high-dose and
68% of the low-dose vaccine recipients presenting a P4-fold response in the HAI assay and 72% of the
high-dose and 61% of the low-dose vaccine recipients exhibiting a P4-fold response in the MN assay.
These promising results support further development. ClinicalTrials.gov number NCT02171819, June
20, 2014.
 2016 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
The 2009 influenza A/H1N1 pandemic illustrates the unpre-
dictability of the influenza virus and supports a call for significant
preparedness efforts across the globe to anticipate new threats.
The effects of an influenza pandemic are likely to be greatest in
resource-limited countries where individuals may be more suscep-
tible to severe outcomes of influenza due to underlying nutritional
deficiencies and concomitant illness, poorer sanitary conditions,
limited access to health care, and the lack of widespread use of vac-cines for influenza as well as against common causes of bacterial
pneumonia [1]. During the influenza A/H1N1 pandemic, vaccine
availability was limited in industrialized countries and was signif-
icantly delayed in low-resource countries.
Since 1996, highly pathogenic influenza A/H5N1 avian viruses
have caused widespread outbreaks in poultry with high mortality
as well as sporadic, severe, and fatal disease in humans [2]. From
2003 through 2016, the World Health Organization (WHO) con-
firmed 850 human cases of influenza A/H5N1 influenza infection,
with 449 deaths [3]. Southeast Asian countries, including Vietnam,
have been disproportionately affected by influenza A/H5N1
accounting for 48.2% of all confirmed influenza A/H5N1 cases
reported during that period. Influenza A/H5N1 infection in animals
is now thought to be endemic in the region [4]. By May 2016, Viet-
nam had reported 125 confirmed human cases, with 62 deaths [5].
Influenza vaccination is considered the optimal approach to
prevent infection and/or limit severe illness. Vaccination could tar-
get individuals that may be exposed to zoonotic transmission, or to
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availability, in the event of a pandemic threat. If an influenza A/
H5N1 pandemic were to occur, the vaccine demand to control it
would be enormous. There is a substantial need for local develop-
ment, production, and stockpiling of influenza A/H5N1 and other
pandemic influenza vaccines (such as A/H7N9) in Vietnam for pan-
demic preparedness. To date, however, no influenza A/H5N1 vac-
cine has been licensed in Vietnam. To address this, the Vietnam
Institute of Vaccines and Medical Biologicals (IVAC) has manufac-
tured pandemic influenza vaccine candidates, including influenza
A/H1N1, A/H5N1, and A/H7N9, as well as a trivalent seasonal vac-
cine candidate under guidance from the Vietnam Ministry of
Health (MOH). IVAC has tested the A/H1N1 vaccine candidate in
clinical trials [6]. We present in this manuscript the results of test-
ing IVAC’s influenza A/H5N1 vaccine candidate in a Phase 1 clinical
trial to initiate the assessment of its safety and immunogenicity.2. Methods
2.1. Study design and implementation
Clinical testing of the influenza A/H5N1 vaccine candidate was
conducted as a Phase 1, double blinded, randomized, placebo-
controlled study at a community clinic in the Ben Luc District, Long
An Province, Vietnam. The primary objective of the study was to
evaluate the safety profile of two intramuscular doses of the vac-
cine, the secondary objective was to evaluate its immunogenicity.
Seventy-five healthy male and female adults, 18–30 years of age,
were enrolled into the trial to receive two doses of vaccine or pla-
cebo three weeks apart. Subjects were randomized to one of the
following three treatment allocations: 32 subjects to 7.5 mcg/dose
vaccine (low-dose), 31 subjects to 15 mcg/dose vaccine (high-
dose), and 12 subjects to placebo. This sample size was selected
to enable at least 30 evaluable subjects in each of the groups to
receive active vaccine. The study was double blinded to study sub-
jects, investigators, and the sponsor until the clinical and labora-
tory data were completed, fully reviewed, and the database was
locked.
In order to be included in the study, subjects had to be healthy
(from medical history and physical exam), aged 18–30 years; will-
ing to provide written informed consent; capable and willing to
complete diary cards; and willing to return for all visits. Females
were asked to utilize reliable birth control measures. Exclusion cri-
teria included: participation in another clinical trial involving
receipt of any non-study vaccine or immunoglobulins within four
weeks of enrollment; current or recent acute illness with or with-
out fever; chronic administration of immunosuppressants; history
of asthma; or hypersensitivity after previous administration of any
vaccine, to any of the vaccine components, including chicken or
egg protein, food, or environmental allergens. Injections of study
product were staggered to allow for an initial safety evaluation
of a sentinel cohort of 19 subjects, which preceded the remainder
of the study group by approximately two to three weeks. Once all
of the volunteers in the sentinel group received a dose of study
vaccine and safety information for seven days post-vaccination
was available, the data were reviewed by a safety monitoring com-
mittee composed of independent experts not associated with the
study, who provided a recommendation to vaccinate the rest of
the study cohort.2.2. Rationale for study design
After consultation with a Product Development Advisory Group
that includes members fromWHO, IVAC, PATH, the US Department
of Health and Human Services’ Biomedical Advanced Research andDevelopment Authority (BARDA), and independent consultants
expert in influenza vaccine development, IVAC chose to evaluate
two dose levels of vaccine, 7.5 and 15 mcg hemagglutinin (HA)
content per 0.5 mL dose given 21 days apart. The doses were cho-
sen because pandemic monovalent vaccines for influenza A/H5N1
strains are known to require a higher HA content than what was
used for influenza A/H1N1 vaccines during the recent pandemic
or used for other human influenza strains, and at the same time
to identify an effective dose lower than the high-doses used with
other H5N1 products (doses of 30–45 mcg have been used by
Sanofi, Microgen, or CSL).2.3. Investigational product
The study product was inactivated, whole virion, monovalent
influenza A/H5N1 vaccine candidate (IVAC/Nha Trang). The vaccine
was produced in embryonated eggs, inactivated with formalin, and
formulated with aluminum hydroxide 0.6 mg/0.5 mL. The follow-
ing two different doses of vaccine were tested: 7.5 mcg (low-
dose) and 15 mcg (high-dose) per 0.5 mL. IVACFLU-A/H5N1 was
filled in single dose vials. Each 0.5 mL dose may have contained
residual amounts of formaldehyde (not more than 0.02%) and
sucrose (not more than 2.0%). Placebo consisting of phosphate buf-
fered saline (PBS) was also manufactured by IVAC. A 0.5 mL single-
dose vial with a pH of 7.2 was used per injection.
Two lots of IVACFLU-A/H5N1 vaccine and one lot of placebo
were used in the study. They were examined for quality control
by the National Institute of Control Vaccine andMedical Biologicals
and were granted the certificate of quality that met the require-
ments on physical properties, pH, aluminum concentration, pro-
tein concentration, potency, identity, general safety, endotoxin,
and sterility.
Study vaccine and placebo were labeled at IVAC in compliance
with MOH’s drug labeling regulations before they were shipped
to Pasteur Institute-Ho Chi Minh City (PI-HCMC) for storage and
to the study site at the Ben Luc District Health Center for use. To
blind the vaccinator and study subjects, a nurse with no other
study duties was responsible for withdrawing study product from
vials according to the randomization schedule. The aluminum
hydroxide adjuvant in the vaccine gave it a slightly different
appearance from the placebo, therefore, in order to maintain the
blinding, the nurse masked the syringe before handing it over to
the vaccinator by covering the original label with an identical
study label containing only the study product code of each subject.2.4. Assigning subjects to study groups
Each subject was assigned a unique screening number after
signing the screening informed consent. Once the subject was con-
sidered to be eligible and he or she signed the consent for the vac-
cine portion of the study, the subject was randomized by assigning
a unique subject identification number sequentially in ascending
order from the randomization schedule. The mechanics of the ran-
domization was the responsibility of a PATH staff scientist not
otherwise involved with the trial. A permuted block randomization
method with the block size of 19 was used to computer generate a
randomization schedule with a pre-specified ratio of 8:8:3 (low-
dose vaccine: high-dose vaccine: placebo). The randomization
schedule was produced using SAS computer software and con-
sisted of the subject identification number and the corresponding
treatment assignment. The first 19 subjects enrolled were treated
as a ‘‘sentinel” cohort before the remaining 57 subjects were
enrolled. For both, the sentinel cohort and the rest of the cohort
the pre-specified randomization ratio of 8:8:3 was used.
Table 1
Demographics and baseline characteristics.
Treatment Vaccine low dose
(N = 31)
Vaccine high dose
(N = 32)
Placebo
(N = 12)
All
(N = 75)
Sex
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The safety profile of IVACFLU-A/H5N1 was evaluated for the
occurrence of: (1) reactions within 60 min of administration as
observed by study staff or reported by subjects; (2) solicited local
and systemic reactions commonly associated with intramuscular
vaccination occurring within seven days of dosing (solicited
adverse events [AEs]); (3) other AEs observed over the three weeks
period after each vaccination; and (4) serious adverse events
(SAEs) occurring within three weeks of receipt of any dose. AEs
and SAEs were recorded according to standard ICH definitions
[7]. These evaluations included clinical findings observed by the
physician or reported by the subject on diary cards (completed
each day for seven days post-vaccination), as well as abnormal lab-
oratory findings from blood specimens collected on Days 7 and 28.
The on-site study principal investigator made all determinations of
potential relatedness of the observed AEs to the study product.
2.6. Immunogenicity assessments
Immune responses to IVACFLU-A/H5N1 were evaluated in
serum samples obtained before the first vaccination (baseline),
and three weeks after each vaccination, on Days 21 and 42. Quali-
fied hemagglutination inhibition (HAI) and microneutralization
(MN) assays were conducted at the PI-HCMC laboratories following
WHO and Centers for Disease Control and Prevention recom-
mended protocols [8,9].
The HAI assay used influenza A/H5N1 virus (NIBRG-14) as the
antigen and was performed in duplicate wells of twofold serial
dilutions of serum. The serum HAI titer is the reciprocal of the
serum dilution in the last well with complete hemagglutination
inhibition [8].
The MN assay determines the titer of neutralizing antibodies
against influenza A/H5N1. The assay was performed in MDCK cell
cultures in duplicate wells at twofold serial dilutions of serum.
The neutralizing antibody titer is the reciprocal of the serum dilu-
tion resulting in 50% drop in viral antigen (nucleoprotein) as
detected by ELISA [9]. The geometric mean titers (GMT) and corre-
sponding confidence intervals were based on a log 10 scale. Exact
confidence intervals were reported for all proportion estimates.
2.7. Statistical considerations
Categorical data were summarized by number and percentage
of subjects falling within each group; continuous variables are
summarized by descriptive statistics including mean, standard
error or deviation, median, minimum, and maximum (a SAS pro-
gram was used). Point estimates and exact 95% confidence inter-
vals for the proportions meeting immunogenicity endpoints were
calculated for the vaccine and placebo groups and the combined
vaccine group; in addition, point estimates and 95% confidence
intervals about the differences in response rates (vaccine – pla-
cebo) were calculated using the Wilson Score Method.Male n (%) 20 19 5 44
64.5 59.4 41.7 58.7
Female n (%) 11 13 7 31
35.5 40.6 58.3 41.3
Age (years)
n 30 31 12 73
Mean 23.7 23.5 23.7 23.6
SD 3.16 3.44 3.28 3.26
Minimum 19 19 18 18
Median 23 23 24 23
Maximum 30 30 28 30
Notes:
N – Total number of subjects under each vaccine group/total.
n – Number of subjects in the category under each vaccine group/total.3. Results
3.1. Disposition of subjects
One hundred and thirty-three subjects were screened at Visit 1.
One subject was a screen failure at Visit 1 and inadvertently
screened at Visit 2, but was never vaccinated. Another screened
subject withdrew before the first vaccination. Seventy-five sub-
jects, aged 18–30 years old, were enrolled and received two injec-
tions of vaccine or placebo 21 days apart. All 75 subjects received
the two study product doses and completed the study. Vaccina-tions took place between June and July 2014. The last subject visit
was conducted on August 24, 2014 and the study completed with
database lock on November 19, 2014.3.2. Demographics and other baseline characteristics
Demographic and baseline characteristics are summarized in
Table 1. Overall, the mean age in the three treatment groups was
23.6 years (range 18–30). Gender distribution was 58.7% male
and 41.3% female. Seventy-five of the subjects (100%) reported their
ethnicity as Kinh. Overall, mean height was 161.19 cm (range:
145.5–179.0); mean weight was 53.42 kg (range: 38.5–82.5); and
mean body mass index was 20.49 kg/m2 (range: 15.9–30.5). Four-
teen (18.7%) subjects had a prior influenza vaccination (only one
in the placebo group).3.3. Vaccine safety
Immediate reactions: No immediate (within 60 min) post-
vaccination reactions were reported after any dose of study
product.
Solicited AEs (local and systemic reactogenicity): Solicited AEs
occurring more than 60 min following vaccination doses through
seven days post-vaccination are summarized in Table 2. After both
vaccinations combined, 26 (83.9%) subjects in the low-dose vac-
cine group, 26 (81.3%) in the high-dose vaccine group, and 4
(33.3%) in the placebo group had at least one solicited AE.
Pain when touching the injection site or pain after injection
were the only reported local reactogenicity. After both vaccinations
combined, at least one solicited local AE was observed in 25
(80.6%) subjects in the low-dose vaccine group, 24 (75.0%) in the
high-dose vaccine group, and 3 (25.0%) in the placebo group. More
local reactions were observed after the first vaccination than after
the second vaccination. After the first vaccination, 25 (80.6%) sub-
jects in the low-dose vaccine group, 23 (71.9%) in the high-dose
vaccine group, and 1 (8.3%) in the placebo group had at least one
solicited local AE. After the second vaccination, 13 (41.9%) subjects
in the low-dose vaccine group, 17 (53.1%) in the high-dose vaccine
group, and 2 (16.7%) in the placebo group had at least one solicited
local AE. All local AEs were mild and short-lived regardless of post-
vaccination period or treatment group.
After both vaccinations combined, at least one event of systemic
reactogenicity was reported by 13 (41.9%) subjects in the low-dose
vaccine group, 14 (43.8%) in the high-dose vaccine group, and 4
(33.3%) in the placebo group. The most common systemic events
were headache (10 or 15.9% of subjects in the combined vaccine
Table 2
Summary of all solicited AEs occurring during the week post-vaccination (combines
data for the two vaccinations).
Vaccine
low dose
Vaccine
high dose
Placebo
Solicited event N = 31 N = 32 N = 12
n % n % n %
Subjects with at least one solicited AE 26 83.9 26 81.3 4 33.3
Subjects with at least one local event 25 80.6 24 75 3 25
Pain when touching injection site 21 67.7 23 71.9 3 25
Painful feeling after injection 18 58.1 16 50 1 8.3
Subjects with at least one systemic event 13 41.9 14 43.8 4 33.3
Chills 1 3.2 3 9.4 0 0
Cough 3 9.7 2 6.3 2 16.7
Fatigue/Malaise 3 9.7 5 15.6 2 16.7
Fever (measured temperature) 0 0 3 9.4 0 0
Sore Throat 2 6.5 2 6.3 2 16.7
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subjects in the combined vaccine groups; 2 [6.7%] subjects in the
placebo group), runny nose (7 [11.1%] subjects in the combined
vaccine groups; 2 [16.7%] subjects in the placebo group), and cough
(5 [7.9%] subjects in the combined vaccine groups, 2 [16.7%] sub-
jects in the placebo group). Additionally, 8 (12.7%) subjects in the
combined vaccine groups were feverish (as defined as having tem-
perature above 37.7 C and above or feeling feverish), but no sub-
jects who received placebo were feverish. Twelve (38.7%) subjects
in the low-dose vaccine group, 12 (37.5%) in the high-dose vaccine
group, and 4 (33.3%) in the placebo group had at least one mild sys-
temic solicited AEs (systemic reactogenicity) after either the first
or second dose (combined). One subject (3.2%) in the low-dose vac-
cine group and two subjects (6.3%) in the high-dose vaccine group
had a moderate AE of headache. More subjects experienced sys-
temic reactogenicity after the first vaccination than after the sec-
ond vaccination for both vaccine groups.
Unsolicited AEs: Unsolicited AEs were defined as safety events
occurring anytime post-vaccination through three weeks after
the second vaccination. A summary of the unsolicited AEs is pre-
sented in Table 3.Table 3
Participants reporting unsolicited AEs by grade/system/organ/class and preferred
term after first and second vaccinations combined.
System/Organ/Class (preferred
term)
Low dose
(N = 31)
High dose
(N = 32)
Placebo
(N = 12)
Injury (Clavicle Fracture) 1⁄ 0 0
Investigations (Alamine
aminotranserferase increased)
1 1 0
Investigations (Bilirubin increased) 3 0 0
Gastrointestinal (apthous
stomatitis)
0 1 0
Gastrointestinal (nausea) 0 1 0
Immune system (food allergy) 0 0 1
Injury (Soft tissue injury) 0 1 0
Infection (Urinary tract infection) 0 0 1
Investigations (Heart rate
increased)
1 0 0
Nervous System (Dizziness) 0 1 0
Nervous System (Dizziness
postural)
1 0 0
Psychiatric (Anxiety) 1 0 0
Psychiatric (Depressed mood) 1 0 0
Reproductive System
(Dysmenorrhea)
0 1 0
Skin and Subcutaneous Tissue
Disorder (Discoloration)
1 0 0
Skin and Subcutaneous Tissue
Disorder (Pruritis)
0 0 1
Other 2 6 1
23 AEs were mild, 4 moderate and 1⁄ severe.Overall, 12 (38.7%) subjects in the low-dose vaccine group, 12
(37.5%) in the high-dose vaccine group, and 4 (33.3%) in the pla-
cebo group had at least one unsolicited AE during the study. The
distribution of unsolicited AEs was similar across treatment groups
and post-vaccination periods, with a couple of exceptions. Five
subjects (7.9%) receiving the vaccine had AEs related to increase
in laboratory measurements or vital signs, while no subjects
receiving a placebo had these AEs.
In the low-dose vaccine group, 8 (25.8%) subjects had at least
one mild unsolicited AE, 3 (9.7%) had a moderate AE, and 1
(3.2%) had a severe AE. In the high-dose vaccine group, 11
(34.4%) subjects had a mild AE and 1 (3.1%) had a moderate AE.
In the placebo group, 4 (33.3%) subjects had a mild AE. Across
treatment groups, more subjects experienced mild AEs after the
first vaccination than after the second vaccination. Three vacci-
nated subjects had moderate bilirubin increases after the second
vaccination (all in the low-dose group), but all returned to mild
promptly and none was considered to be clinically significant.
The single severe unsolicited AE occurred in a subject who experi-
enced a left clavicle bone fracture deemed unrelated to vaccina-
tion. No SAEs were reported in the study and no AEs led to study
discontinuation.3.4. Immunogenicity
Immune responses were measured at baseline (pre-
vaccination) and 21 days after each vaccine dose (Day 21 and
Day 42). The proportion of subjects achieving an HAI titer P1:40
after each dose and those achieving a P4-fold rise in HAI titer
are presented in Tables 4A and B, respectively. Seven of 31
(22.6%) subjects receiving the low-dose of vaccine and 9 of 32
(28.1%) subjects receiving the high-dose achieved an HAI titer
P1:40 after first vaccination. The number increased to 13
(41.9%) and 18 (56.3%) subjects after the second vaccination for
low- and high-dose vaccine, respectively. No placebo subjects
reported HAI titer P1:10 at any visit. A significant difference in
response rates was observed after first vaccination for high-dose
vaccine (95% CI: 0.82, 45.37) and after second vaccination for both
low and high vaccine doses compared to placebo. No significant
difference in response rates were observed between the low-dose
and the high-dose after either vaccination.
The proportion of subjects achieving aP4-fold rise in HAI anti-
body titer between doses (baseline to post-dose 1 and baseline to
post-dose 2) is presented in Table 4B. Such responses were
observed in 35.5% of low-dose recipients and 37.5% of high-dose
recipients after the first vaccination. The corresponding serore-
sponse rate between baseline and post-second dose were 67.7%
and 71.9% for low-dose and high-dose vaccine recipients,
respectively.
Table 5 summarizes the GMT and GMT ratio (GMTR) for HAI
antibodies. No HAI antibodies were detected in any of the 75 par-
ticipants at baseline. GMT rose to 12.8 (low-dose) and 11.9 (high-
dose) after the first vaccination and to 24.5 (low-dose) and 27.1
(high-dose) after the second vaccination. The corresponding GMTR
rises with respect to placebo were 2.56 and 2.38 after the first vac-
cination, and 4.89 and 5.42 after the second vaccination for low
and high-doses, respectively. The GMTs and GMTRs in the vaccine
groups were significantly higher (i.e., the lower bound of the 95%
confidence interval for the GMT ratio or GMTR ratio >1.0) than pla-
cebo, but no difference in GMTs or GMTRs was found between the
low-dose and high-dose vaccine groups at either dose.
In the MN assay, a P4-fold rise was observed from baseline to
post-first vaccination in 5 of 31 (16.1%) and 7 of 32 (21.9%) subjects
for low-dose and high-dose vaccine, respectively. Similar P4-fold
rise between baseline and second vaccination were seen 19 out
Table 4
Immune response rates by HAI.
AP 1:40 titer Response rates Difference in rates (95% confidence intervals)b
Treatment Group n/N (%) [95% CI]a vs. Placebo vs. Vaccine low dose
Post dose 1
Placebo 0/12 (0.0) [ 0.00, 26.46]
Combined vaccine 16/63 (25.4) [15.27, 37.94] 25.4 (0.51, 37.34)
Vaccine low dose 7/31 (22.6) [ 9.59, 41.10] 22.6 (4.12, 39.81)
Vaccine high dose 9/32 (28.1) [13.75, 46.75] 28.1 (0.82, 45.37) 5.5 (15.78, 26.10)
Post dose 2
Placebo 0/12 (0.0) [ 0.00, 26.46]
Combined vaccine 31/63 (49.2) [36.38, 62.11] 49.2 (22.18, 61.24)
Vaccine low dose 13/31 (41.9) [24.55, 60.92] 41.9 (13.14, 59.23)
Vaccine high dose 18/32 (56.3) [37.66, 73.64] 56.3 (26.68, 71.83) 14.3 (9.89, 36.31)
BP 4-fold rise Response rates Difference in rates (95% confidence intervals)b
Baseline to Post dose 1
Placebo 0/12 (0.0) [ 0.00, 26.46]
Combined vaccine 23/63 (36.5) [24.73, 49.60] 36.5 (9.97, 48.85)
Vaccine low dose 11/31 (35.5) [19.23, 54.63] 35.5 (7.30, 53.05)
Vaccine high dose 12/32 (37.5) [21.10, 56.31] 37.5 (9.21, 54.75) 2.0 (20.81, 24.46)
Post dose 1 to Post dose 2
Placebo 0/12 (0.0) [0.00, 26.46]
Combined vaccine 20/63 (31.7) [20.58, 44.69] 31.7 (5.45, 44.00)
Vaccine low dose 9/31 (29.0) [14.22, 48.04] 29.0 (1.55, 46.59)
Vaccine high dose 11/32 (34.4) [18.57, 53.19] 34.4 (6.39, 51.69) 5.3 (1.7, 26.96)
Baseline to Post dose 2
Placebo 0/12 (0.0) [0.00, 26.46]
Combined vaccine 44/63 (69.8) [56.98, 80.77] 69.8 (42.70, 79.76)
Vaccine low dose 21/31 (67.7) [48.63, 83.32] 67.7 (37.78, 81.43)
Vaccine high dose 23/32 (71.9) [53.25, 86.25] 71.9 (42.12, 84.44) 4.1 (17.89, 25.76)
Notes:
N – Total number of subjects in each group; n – Total number of subjects meeting the event.
a 95% confidence interval for single proportion is calculated using Exact Clopper-Pearson method.
b The 95% two sided confidence intervals for the difference in Immune response rates are constructed based on Newcombe-Wilson score method done for Per protocol
population.
Table 5
GMT for HAI antibody and GMTRs.
GMT GMT ratio
Timepoint Vac low dose
(N = 31)
Vac high dose
(N = 32)
Any vaccine
(N = 63)
Placebo
(N = 12)
Vac low dose/
Placebo
Vac high dose/
Placebo
Any Vaccine/
Placebo
Vac high dose/Vac
low dose
Baseline
GMT 5.0 5.0 5.0 5.0 – – – –
95% CI (5.00, 5.00) (5.00, 5.00) (5.00, 5.00) (5.00, 5.00) – – – –
Post dose 1
GMT 12.8 11.9 12.3 5.0 12.9 – – –
95% CI (7.95,20.58) (8.17,17.31) (9.19,16.53) (5.00, 5.00) – – – –
Ratio of GMTa – – – – 2.6 2.4 2.5 0.9
95% CI for – – – – (1.194, 5.480) (1.291, 4383) (1.256, 4,838) 0.515, 1.681)
Ratio of GMT – – – – – – – –
Post dose 2
GMT 24.5 27.1 25.8 5.0 – – – –
95% CI (15.51,38.58) (19.98,36.71) (19.77,33.57) (5.00, 5.00) – – – –
Ratio of GMT – – – – 4.9 5.4 5.2 1.1
95% CI for – – – – (2.358,10.148) (3.302, 8.885) (2.804, 9.464) (0.650, 1.888)
Ratio of GMT – – – – – – – –
Notes:
N – Total number of subjects in each group; n - the number of subjects with antibody titers.
Geometric Mean titer (GMT) and 95% CIs are calculated by taking the anti-natural log of the means and 95% CI of the log transformed titers.
Confidence intervals are constructed using t distribution on the natural log transformed titer values and then back transformed into the original values.
a Ratio of GMT = GMT for test/GMT for control.
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(71.9%) after the high-dose (Table 6).
Neutralization GMTs after the first vaccination with the low-
dose or high-dose were similar (9.4), and rose to 21.9 for thelow-dose and to 23.3 for the high-dose after the second vaccination
(Table 7). No neutralization was detected in baseline sera from any
of the participants or in post-vaccination sera from the placebo
recipients. GMTRs for neutralizing antibodies with respect to
Table 6
Immune response rates by neutralization (P4-fold rise).
Difference in rates (95% CI)a
Treatment group n/N (%) vs. Placebo vs. Vaccine low dose
Baseline to Post dose 1
Placebo 0/12(0.0)
Combined vaccine 12/63(19.0) 19.0 (6.43, 30.41)
Vaccine low dose 5/31(16.1) 16.1 (9.75, 32.63)
Vaccine high dose 7/32(21.9) 21.9 (4.69, 38.75) 5.7 (14.01, 24.89)
Baseline to Post dose 2
Placebo 0/12(0.0)
Combined vaccine 42/63(66.7) 66.7 (39.48, 77.05)
Vaccine low dose 19/31(61.3) 61.3 (31.41, 76.27)
Vaccine high dose 23/32(71.9) 71.9 (42.12, 84.44) 10.6 (12.26, 32.10)
a The 95% two sided Cis for the differences are constructed based on the Newcombe-Wilson method.
Table 7
GMT and GMTR for neutralizing antibody.
Timepoint GMT GMT ratio
Vac low dose
(N = 31)
Vac high dose
(N = 32)
Any vaccine
(N = 63)
Placebo
(N = 12)
Vac low dose/
Placebo
Vac high dose/
Placebo
Any Vaccine/
Placebo
Vac high dose/
Vac low dose
Baseline
GMT 5 5 5 5 – – – –
95% CI (5.00, 5.00) (5.00, 5.00) (5.00, 5.00) (5.00, 5.00) – – – –
Post dose 1
GMT 9.4 9.4 9.4 5 – – – –
95% CI (5.99,14.60) (6.52,13.46) (7.09,12.36) (5.00, 5.00) – – – –
Ratio of GMT – – – – 1.87 1.87 1.87 1
95% CI for – – – – (0.916,3.818) (1.039,3.381) (0.988,3.547) (0.572,1.756)
Ratio of GMT – – – – – – – –
Post dose 2
GMT 21.9 23.3 22.6 5 – – – –
95% CI (13.91, 34.38) (16.54,32.76) (17.16,29.70) (5.00, 5.00) – – – –
Ratio of GMT – – – – 4.37 4.65 4.51 1.06
95% CI for – – – – (2.120,9.026) (2.669,8.119) (2.404,8.477) (0.612,1.850)
Ratio of GMT – – – – – – – –
Notes:
N – Total number of subjects in each group; n - the number of subjects with non-missing antibody titer results at both, pre- and post-vaccination.
Geometric Mean titer (GMT) and 95% CIs are calculated by taking the anti-natural log of the means and 95% CI of the log transformed pre- and post-vaccination titers.
The CIs are constructed using t distribution on the natural log transformed values of the antibody titer, the values are then transformed into the original values.
Titer below the lowest limit of quantification (i.e. below the starting dilution of assay reported as ‘‘<10”) was set to half that limit (i.e., 10/2 = 5).
5454 T.L. Phan et al. / Vaccine 34 (2016) 5449–5456placebo were 1.9 for both the low-dose and high-dose after first
vaccination and 4.4 (low-dose) and 4.7 (high-dose) after second
vaccination.
Table 8 presents a detailed analysis of HAI and MN responses at
the individual participant level. Taking into account the two assays
employed, the overallP4-fold seroresponse rates were 68% for the
low-dose recipients (i.e., 22 of the 31 participants presented either
an HAI or a neutralization response), and 72% for the high-dose
recipients. Further, if a twofold change were to be considered a
seroresponse, all but three of the low-dose and one of the high-
dose responses presented evidence of immune priming (post hoc
analysis). None of the placebo recipients presented a P2-fold
response.4. Discussion
Since the first human case of influenza A/H5N1 detected twenty
years ago, over 800 human cases with a fatality rate of over 50%
have been recorded worldwide. Continuous reintroduction and
spread of the virus in poultry in several Asian countries has had
a devastating economic impact. While transmission to humans is
rare, mutations that can allow efficient transmission between
humans could result in a pandemic of enormous consequences.More than two dozen inactivated influenza A/H5N1 vaccines
have been produced around the world. For a few of them, stock-
piles are available in a few resource-rich countries. Some
resource-limited countries are receiving technical and logistical
support from WHO to develop their own vaccines for stockpiling
or for use in high-risk populations. Vietnam is one such country
where the MOH-affiliated vaccine manufacturer, IVAC, has
received support to develop the influenza A/H5N1 vaccine candi-
date tested in this study. Two injections of two different dose levels
(7.5 and 15 mcg) of the vaccine or placebo were administered to 75
subjects in a blinded study. The vaccine was well tolerated with no
serious or severe local or systemic reactogenicity at either dose
tested. No immediate post-vaccination reactions were reported
and the solicited reactions observed within the seven days post-
vaccination were all mild and well tolerated, consisting primarily
of spontaneous pain at the injection site or pain when touching
it. No induration, redness, or edema were observed. Few solicited
systemic events were recorded over the week after each vaccina-
tion. Unsolicited AEs were similar in frequency and severity among
vaccine and placebo recipients, and in no case were deemed to be
related to administration of the investigational product. Of all the
unsolicited AEs observed, only three were more than mild in sever-
ity (one in a subject in the low-dose vaccine group and two in sub-
jects in the high-dose group). None of the events observed was
Table 8
HAI and MN responses for each participant.
ID d21 d42
fold 
rise
d21 d42
fold 
rise
ID d21 d42
fold 
rise
d21 d42
fold 
rise
ID d21 d42
fold 
rise
d21 d42
fold 
rise
67 640 640 128 1280 1280 256 35 160 160 32 320 320 64 6 5 5 1 5 5 1
16 40 320 64 5 160 32 60 20 160 32 10 160 32 9 5 5 1 5 5 1
4 160 160 32 80 80 16 12 10 80 16 5 40 8 13 5 5 1 5 5 1
46 160 160 32 57 80 16 34 80 80 16 40 40 8 26 5 5 1 5 5 1
25 80 80 16 80 113 23 28 40 40 8 40 57 11 36 5 5 1 5 5 1
69 5 40 8 10 40 8 29 20 40 8 5 40 8 37 5 5 1 5 5 1
3 5 40 8 7 20 4 63 40 40 8 40 40 8 41 5 5 1 5 5 1
27 40 40 8 10 20 4 66 5 40 8 14 40 8 54 5 5 1 5 5 1
30 20 40 8 10 40 8 73 5 40 8 5 40 8 55 5 5 1 5 5 1
33 10 40 8 5 40 8 19 40 40 8 5 20 4 59 5 5 1 5 5 1
71 40 40 8 7 28 6 22 5 40 8 5 20 4 70 5 5 1 5 5 1
8 5 40 8 5 20 4 72 10 40 8 5 80 16 75 5 5 1 5 5 1
21 20 40 8 5 10 2 2 40 40 8 40 40 8 GM 5 5 1 5 5 1
43 5 20 4 5 40 8 23 20 40 8 10 40 8
14 20 20 4 20 20 4 32 40 40 8 40 40 8
57 5 20 4 7 40 8 44 40 40 8 20 20 4
38 10 20 4 7 20 4 51 40 40 8 10 20 4
40 5 20 4 5 20 4 5 5 40 8 5 5 1
58 10 20 4 5 20 4 11 10 20 4 10 20 4
49 20 20 4 5 10 2 47 5 20 4 5 20 4
56 5 20 4 5 10 2 48 5 20 4 5 20 4
31 5 10 2 5 5 1 50 5 20 4 5 20 4
45 10 10 2 5 40 8 17 5 20 4 5 7 1
10 5 10 2 5 5 1 24 5 10 2 5 10 2
52 5 10 2 5 5 1 53 5 10 2 5 5 1
1 5 5 1 5 5 1 62 5 10 2 5 20 4
15 5 5 1 5 5 1 74 5 10 2 5 20 4
20 5 5 1 5 5 1 18 5 10 2 5 10 2
65 5 5 1 7 10 2 39 5 10 2 5 10 2
64 5 5 1 5 10 2 42 10 10 2 5 10 2
68 5 5 1 10 10 2 61 5 10 2 7 10 2
GM* 12.8 24.5 4.9 9.4 21.9 4.4 7 5 5 1 5 5 1
GM 11.9 27.1 5.4 9.4 23.3 4.7
None of the subjects had measurable anbodies at baseline
GM* = Geometric Mean Titer or fold rise
no increase in ter
2 fold  increase in ter
4 fold increase in ter
>= 4 fold increase & ter >=40
LOW DOSE HIGH DOSE PLACEBO
HAI MICRONEUT HAI MICRONEUT HAI MICRONEUT
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safety data observed justifies continuing the development of this
vaccine candidate in larger populations.
The immunological assays conducted on post-vaccination sera
demonstrated rates and levels of immune response similar to those
of other influenza A/H5N1 inactivated vaccines. Overall, about 70%
of the recipients presented a fourfold or greater seroresponse in the
HAI assay, with slightly more frequent responses to the high-dose,
but without a demonstrable statistically significant difference.
Similar response rates were observed in the neutralization assay
employed. None of the participants had demonstrable pre-
existing antibodies to influenza A/H5N1 virus and none of the
placebo recipients developed a seroresponse. Given the latter
observation, an ad hoc analysis was conducted that showed that
all but one participant in the high-dose group, and all but three
participants in the low-dose group would have been considered
vaccine responders if a twofold rise in titer from baseline was usedas the criterion for immunogenicity. Furthermore, such responses
were already observed in about half of the subjects following the
first vaccine dose, attesting to the ability of the vaccine to prime
the immune system in naïve subjects.
The frequency and magnitude of responses was lower than
those observed with seasonal inactivated influenza vaccines (see
DD Anh et al. in this issue of Vaccine), an observation that has been
made for all other H5 and H7 avian influenza vaccines tested in
clinical trials [10,11]. As this was anticipated, and following the
lead from other studies, the vaccine consisted of a whole virus
preparation. Whole virus vaccines have indeed the potential to
be more immunogenic than split-virus or subunit vaccines in pre-
viously unvaccinated populations [12,13]. Moreover, and again,
following the lead from prior studies the vaccine was adjuvanted
with aluminum hydroxide [14,15].
While recognizing that significant variability occurs across dif-
ferent laboratories in the use of HAI and microneutralization
5456 T.L. Phan et al. / Vaccine 34 (2016) 5449–5456assays to evaluate influenza vaccines, our vaccine compares favor-
ably to similar vaccines developed/tested in the United States [16],
using a 15 mcg dose of a H5 subunit vaccine, and are similar to the
ones reported for aluminum hydroxide adjuvanted vaccines man-
ufactured in Japan [17], Russia [18], China [19], and Thailand
[20]. Higher immune response rates and titers have been observed
with the use of ASO3 adjuvant [21] or with MF59 adjuvant [22,23].
The safety and immunogenicity results of this Phase 1 study are
very promising and support further development of the product
towards licensure. Before moving into a pivotal Phase 3 study,
however, we decided to investigate the potential that a higher vac-
cine dose (30 mcg) may be more immunogenic than the current
doses tested, in a study that is now ongoing.Author contribution
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